EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Anticancer Activity of Monosaccharides: Perspectives and Outlooks

Niamh McCallum, Mohammad Najlah iD

Cancers · 06.08.2024 · 16 (16) · 2775

DOI: 10.3390/cancers16162775 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 06.08.2024. Verfasst von Niamh McCallum und 1 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Research Group, School of Allied Health, Faculty of Health, Education, Medicine and Social Care, Anglia Ruskin University, Bishops Hal…. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 164 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A major hallmark of cancer is the reprogramming of cellular metabolism from oxidative phosphorylation (OXPHOS) to glycolysis, a phenomenon known as the Warburg effect. To sustain high rates of glycolysis, cancer cells overexpress GLUT transporters and glycolytic enzymes, allowing for the enhanced uptake and consumption of glucose. The Warburg effect may be exploited in the treatment of cancer; certain epimers and derivatives of glucose can enter cancer cells and inhibit glycolytic enzymes, stunting metabolism and causing cell death. These include common dietary monosaccharides (ᴅ-mannose, ᴅ-galactose, ᴅ-glucosamine, ʟ-fucose), as well as some rare monosaccharides (xylitol, ᴅ-allose, ʟ-sorbose, ʟ-rhamnose). This article reviews the literature on these sugars in in vitro and in vivo models of cancer, discussing their mechanisms of cytotoxicity. In addition to this, the anticancer potential of some synthetically modified monosaccharides, such as 2-deoxy-ᴅ-glucose and its acetylated and halogenated derivatives, is reviewed. Further, this article reviews how certain monosaccharides can be used in combination with anticancer drugs to potentiate conventional chemotherapies and to help overcome chemoresistance. Finally, the limitations of administering two separate agents, a sugar and a chemotherapeutic drug, are discussed. The potential of the glycoconjugation of classical or repurposed chemotherapy drugs as a solution to these limitations is reviewed.

Schlagwörter

Stichwörter der Autor:innen

anticancer drugsantitumour therapyglycolysismonosaccharidesnatural productssugars

Autor:innen und Institutionen

  • Pharmaceutical Research Group, School of Allied Health, Faculty of Health, Education, Medicine and Social Care, Anglia Ruskin University, Bishops Hall Lane, Chelmsford CM1 1SQ, UK.

ORCID-Profile: Mohammad Najlah

Zitieren

APA

McCallum, N., & Najlah, M. (2024). The Anticancer Activity of Monosaccharides: Perspectives and Outlooks. Cancers, 16(16), 2775. https://doi.org/10.3390/cancers16162775

Vancouver

McCallum N, Najlah M. The Anticancer Activity of Monosaccharides: Perspectives and Outlooks. Cancers. 2024;16(16):2775. doi:10.3390/cancers16162775

BibTeX
@article{McCallum2024,
  author = {McCallum, Niamh and Najlah, Mohammad},
  title = {The Anticancer Activity of Monosaccharides: Perspectives and Outlooks},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {16},
  pages = {2775},
  doi = {10.3390/cancers16162775}
}
Kostenlos starten →